Article Impact Level: HIGH Data Quality: STRONG Summary of Trends in Cardiovascular Medicine, S1050173825000982. https://doi.org/10.1016/j.tcm.2025.07.005 Dr. John Dunn et al.
Points
- Practicing cardiologists should prioritize the highest tolerated doses of potent statins, such as rosuvastatin and atorvastatin, as the foundational therapy for treating and preventing cardiovascular disease.
- Therapeutic lifestyle changes are crucial but underutilized, with 40% of U.S. adults having metabolic syndrome and only 21% meeting minimum daily requirements for physical activity.
- Adjunctive therapies such as ezetimibe and evolocumab should be reserved for select high-risk patients who do not achieve LDL cholesterol goals with maximal statin therapy alone.
- Among omega-3s, only icosapent ethyl has demonstrated significant additional benefit, reducing major cardiovascular events by 25% when added to high-potency statins in a large trial.
- Aspirin is recommended for most secondary prevention patients, but its use in primary prevention requires careful judgment, weighing the risk of occlusion against the risk of major bleeding.
Summary
This editorial argues for an aggressive, statin-centric approach to managing and preventing cardiovascular disease (CVD). The authors assert that, in conjunction with therapeutic lifestyle changes, the primary pharmacologic intervention should be the highest tolerated doses of potent statins, namely rosuvastatin and atorvastatin. This recommendation is based on the robust totality of evidence from randomized trials showing their superior and consistent benefit in lowering LDL cholesterol. Population statistics underscore the urgency for effective pharmacotherapy, as approximately 40% of U.S. adults have metabolic syndrome and only 21% meet minimum physical activity guidelines, placing them at a cardiovascular risk equivalent to patients with prior events.
The paper offers a cautious perspective on adjunctive therapies, suggesting they are often used more widely than evidence supports. It cites the IMPROVE-IT trial, in which ezetimibe added to simvastatin showed only a minor benefit, and the FOURIER trial, which demonstrated evolocumab’s efficacy primarily in secondary prevention for patients with familial hypercholesterolemia who were already on maximal statin therapy. Therefore, these agents should be reserved for select, high-risk patients who fail to achieve LDL goals with statins alone. A similar critical view is applied to omega-3 fatty acids, where only icosapent ethyl showed significant added benefit in the REDUCE-IT trial, reducing major cardiovascular events by 25% with a number needed to treat of 21.
Finally, the authors provide practical recommendations for clinicians. They advise starting with the highest statin dose and titrating down if necessary, as most patients remain on their initial dose. Aspirin’s role is also clarified: it should be prescribed for most secondary prevention patients, where its benefits are at least additive to those of statins. In primary prevention, however, aspirin should only be considered after statins if the patient’s residual risk of an occlusive event outweighs the risk of major bleeding. This tiered, evidence-based strategy aims to maximize the proven benefits of statins before escalating to other therapies.
Link to the article: https://www.sciencedirect.com/science/article/abs/pii/S1050173825000982
References Dunn, J., & Hennekens, C. H. (2025). Low density lipoprotein (Ldl) and beyond in the treatment and prevention of cardiovascular disease. Trends in Cardiovascular Medicine, S1050173825000982. https://doi.org/10.1016/j.tcm.2025.07.005
